Welcome to Greenshoots
Greenshoots is a collection of fresh intellectual property insight, analysis and commentary on the issues that matter most to those who invent, manage and protect intellectual property, written by the IP specialists of Appleyard Lees.
Now that you’re here, why not take a look around?
The legality of videoconference oral proceedings – outcome of G1/21
The EPO’s highest judicial body, the EBoA, has today released its “order” on the legality of videoconference oral proceedings.
Sir Ringo Starr puts his ring on it with an agreement
As the Ringo Starr case shows, despite some tricky issues to navigate around, the parties were able to reach an agreement and have likely saved long run costs of fighting a lengthy legal battle!
Navigating IP for start-ups: a live IP audit with a fictitious start-up
In this virtual event, Appleyard Lees patent attorney Paul Beynon and trade mark attorney Olivia Hamilton ran a mock IP audit, with partner Richard Bray playing the part of a start-up client.
A brief guide to patenting diagnostic inventions in Europe
Trainee patent attorney Andrew Mullins looks at how to obtain patent protection for inventions within the diagnostic field.
The Greenshoots Podcast by Appleyard Lees – episode 17: how to avoid intellectual property disputes, and what to do if they arise
This episode of the podcast features Bill Lister and Chris Thomas, specialist IP solicitors who help clients in the UK and around the world manage IP disputes in a commercially and legally sensible way.
The University of Cambridge fight over Cambridge Blue
In a recent decision, the UK Intellectual Property Office found in favour of Cambridge University and upheld an opposition against a trade mark application for CAMBRIDGE BLUE.
Exhaustion regime post-Brexit – A new UK consultation
The Brexit transition period came to an end on 31 December 2020 and as of 1 January 2021 the UK was no longer bound by EU legal framework. Before the UK left the EU, the UK was party to the EU’s regional exhaustion of IP rights regime.
Directors and IP – getting up close and personal
The received wisdom is that company directors can escape liability by sheltering behind the “corporate veil”. But is this true in IP cases?
Is it worth patenting your AI tools for drug discovery?
Often, when the AI identifies a drug, and experiments confirm it is useful for the intended purpose, the drug can be patented. But what about the AI itself – can the AI be protected by patents, and should you try to?
